TITTLE: Big challenges loom for nursing facilities
Boom in elderly population and falling reimbursements expected to cause squeeze.
Boom in elderly population and falling reimbursements expected to cause squeeze.
But major Indianapolis-area hospitals still prefer personal referrals
Proponents of such policies say they are the future of work—even as they acknowledge that it may take a generation for them to be widely accepted. Some workers, however, are fearful.
A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing a similar drug.
For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward the drugmaker’s diabetes portfolio.
The Indiana Supreme Court this week will consider whether hospital billing practices should be put on trial. The state’s highest court will hear oral arguments Thursday in a case in which two uninsured patients have sued Indiana University Health for charging them much higher prices than it would have charged insured patients.
The health care company that once promised to create 900 jobs in central Indiana has agreed to cease operations after a major lender moved to foreclose on the struggling Indianapolis-based business.
Health care firms have opened a flurry of clinics at Hoosier employers the past two years as businesses increasingly embrace the concept as a way to restrain employee health costs.
When the same MRI at one facility costs $600 and at another costs $2,200, Dr. Robert Gregori would call that a business opportunity.
Authorities have arrested two Cuban brothers in the 2010 theft of about $80 million in Eli Lilly and Co. prescription drugs from a Connecticut warehouse, a robbery described as one of the biggest pharmaceutical heists in history, the U.S. attorney’s office said Thursday.
More than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed at previously.
The market for testosterone-replacement treatments is growing, but health experts say overuse of the drugs can be dangerous.
BioCrossroads Inc. has raised an $8.25 million seed fund in its second attempt to help startup life sciences companies grow to the point where they can attract venture capital or a corporate funder.
Health insurance customers in Indiana will get an estimated $16.5 million in rebates this year, but the average amount received per person will be less than the national average and less than 3 percent of the total cost of coverage.
A Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and Co.'s Cialis or Pfizer Inc.’s Viagra, has received U.S. regulatory approval.
More than 3 million health insurance policyholders and thousands of employers will share $1.3 billion in rebates this year, thanks to health care reforms, a research group said Thursday. Indianapolis-based WellPoint Inc. is expected to return $94 million.
Indiana-based orthopedic implant maker Zimmer Holdings Inc. on Thursday reported a fractional increase in first-quarter profit on higher sales in all global regions, particularly the Asia Pacific.
David Karandos failed to make fine payments due March 1 and April 1, and Securities Commissioner Chris Naylor has ordered him to appear at a May hearing to make the case why “additional consequences” aren’t warranted.
Indianapolis-based WellPoint Inc. sees a $100 billion market in the states it serves to provide managed care for poor, elderly patients in the Medicare and Medicaid programs.